Xlife Sciences Past Earnings Performance

Past criteria checks 4/6

Xlife Sciences has been growing earnings at an average annual rate of 10.8%, while the Life Sciences industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 14.1% per year. Xlife Sciences's return on equity is 4.3%, and it has net margins of 2144.5%.

Key information

10.8%

Earnings growth rate

4.3%

EPS growth rate

Life Sciences Industry Growth17.6%
Revenue growth rate14.1%
Return on equity4.3%
Net Margin2,144.5%
Next Earnings Update25 Apr 2025

Recent past performance updates

Concerns Surrounding Xlife Sciences' (VTX:XLS) Performance

Sep 26
Concerns Surrounding Xlife Sciences' (VTX:XLS) Performance

Xlife Sciences' (VTX:XLS) Problems Go Beyond Weak Profit

Apr 28
Xlife Sciences' (VTX:XLS) Problems Go Beyond Weak Profit

Recent updates

Concerns Surrounding Xlife Sciences' (VTX:XLS) Performance

Sep 26
Concerns Surrounding Xlife Sciences' (VTX:XLS) Performance

Xlife Sciences' (VTX:XLS) Problems Go Beyond Weak Profit

Apr 28
Xlife Sciences' (VTX:XLS) Problems Go Beyond Weak Profit

Revenue & Expenses Breakdown

How Xlife Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SWX:XLS Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2412130
31 Mar 2411840
31 Dec 2311550
30 Sep 2311650
30 Jun 2311660
31 Mar 2311560
31 Dec 2211450
30 Sep 2213250
30 Jun 2214950
31 Mar 2215160
31 Dec 2115360
30 Sep 2113450
30 Jun 2111450
31 Mar 2101840
31 Dec 2002130
30 Sep 2001420
30 Jun 201620
31 Mar 201310
31 Dec 191110

Quality Earnings: XLS has a large one-off gain of CHF38.6M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: XLS's current net profit margins are higher than last year .


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XLS's earnings have grown by 10.8% per year over the past 5 years.

Accelerating Growth: XLS's earnings growth over the past year (31.7%) exceeds its 5-year average (10.8% per year).

Earnings vs Industry: XLS earnings growth over the past year (31.7%) exceeded the Life Sciences industry 4.3%.


Return on Equity

High ROE: XLS's Return on Equity (4.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel JelovcanStifel, Equities Research
Ulrich HuwaldWarburg Research GmbH